在多重系统缩中的试点治疗教育计划:安全,生活质量和满意度来自基于国家注册的纵向研究
A Cámara1, Y Compta1, M Baixauli2
1Parkinson's Disease & Movement Disorders Unit and Hospital de Dia de Malalties Neurodegeneratives (HDMND), Neurology Service, Hospital Clínic / IDIBAPS / CIBERNED / European Reference Network for Rare Neurological Diseases (ERN-RND / Institut de Neurociències, Universitat de Barcelona, Catalonia, Spain.
Parkinsonism & related disorders
|May 12, 2024
概括
针对多系统性缩 (MSA) 患者和护理人员的医疗保健教育计划是可行的,令人满意和安全的. 该计划在六个月内没有显示患者报告结果的显著恶化.
科学领域:
- 神经学 神经学
- 康复医学 康复医学 康复医学
- 患者教育 患者教育
背景情况:
- 治疗教育计划是为慢性疾病建立的.
- 对于多系统性缩 (MSA) 存在有限的证据.
- 需要评估MSA患者和护理人员的程序有效性和安全性.
研究的目的:
- 评估针对MSA (PwMSA) 患者及其照顾者的综合治疗教育计划的有效性和安全性.
主要方法:
- 与16名PwMSA和护理人员在4组中的前性纵向研究.
- 八个跨学科的会议涵盖了MSA护理的各个方面.
- 标准化尺度 (UMSARS,NMSS,PDQ39,EQ5,Zarit) 在基线和6个月后使用.
- 在每次会议结束后填写满意度调查问卷 (EduPark,Likert).
主要成果:
- 对该计划的高度坚持 (94.92%).
- 根据PwMSA和护理人员的满意度,或根据疾病严重程度/性别,没有显著的差异.
- 报告的语音,呼吸和职业治疗课程的满意度更高.
- 在6个月的任何结果尺度上都没有显著恶化.
结论:
- 治疗教育计划对PwMSA和护理人员来说是可行的,令人满意和安全的.
- 该计划的教育材料将与新的MSA案例共享.
- 这种干预措施对管理MSA等慢性疾病充满希望.
相关概念视频
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.


